- RecruitingPHASE3
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
This study is testing a new medicine called Depemokimab for people aged 12 and over with a type of asthma that often causes flare-ups. It aims to see if this new medicine can help reduce these flare-ups better than usual treatments or a dummy medicine.
For: AsthmaUnited States · United Kingdom - CompletedPhase III
Seasonal asthma exacerbation prevention with depemokimab
This study is testing a new medicine called depemokimab to see if it can prevent asthma attacks during autumn and winter. It's for adults with moderate-to-severe asthma and will compare the new medicine to a dummy treatment.
For: Moderate-to-severe asthmaUnited Kingdom - Active not recruitingPHASE3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This 52-week study is testing a new drug, depemokimab, for adults with uncontrolled Hypereosinophilic Syndrome (HES). It aims to see if depemokimab is effective and safe compared to a placebo, alongside their usual HES treatment.
For: Hypereosinophilic SyndromeUnited States · Argentina · Australia - RecruitingPHASE3
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
This study looks at a new asthma medicine, Depemokimab, to see how it affects people's lungs. It focuses on those with a specific type of asthma where their airways get inflamed and swollen, causing breathing problems.
For: AsthmaUnited States · Belgium · Canada - Active not recruitingPHASE3
Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)
This study is looking at two medicines, Depemokimab and Mepolizumab, for adults with a rare condition called EGPA. We want to see how well they work and if they are safe when patients are already having standard treatment.
For: Eosinophilic Granulomatosis With PolyangiitisUnited States · Argentina · Austria - RecruitingPHASE3
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
This study is testing a new medicine, depemokimab, for adults aged 40-80 with moderate to severe Chronic Obstructive Pulmonary Disease (COPD) and a specific type of inflammation. It aims to see if depemokimab improves symptoms and is safe when added to their usual inhaler treatment.
For: Pulmonary Disease, Chronic ObstructiveUnited States · Argentina · Australia - RecruitingPHASE3
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
This study is testing a new medicine, depemokimab, for people with moderate to severe COPD that involves a specific type of inflammation. We want to see if starting this medicine early helps improve their breathing and reduce flare-ups.
For: Pulmonary Disease, Chronic ObstructiveUnited States · Australia · Bulgaria